CHF26.10
4.22% yesterday
SIX Swiss Exchange, Sep 02, 05:31 pm CET
ISIN
CH1110760852
Symbol
PPGN

PolyPeptide Stock price

CHF26.10
+4.40 20.28% 1M
+6.00 29.85% 6M
-2.30 8.10% YTD
-7.50 22.32% 1Y
-10.84 29.34% 3Y
-36.40 58.24% 5Y
-36.40 58.24% 10Y
-36.40 58.24% 20Y
SIX Swiss Exchange, Closing price Tue, Sep 02 2025
-1.15 4.22%

Key metrics

Basic
Market capitalization
CHF900.1m
Enterprise Value
CHF932.5m
Net debt
CHF32.4m
Cash
CHF71.8m
Shares outstanding
33.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.6 | 2.4
EV/Sales
2.7 | 2.5
EV/FCF
30.9
P/B
2.9
Dividends
DPS
CHF0.00
Yield 1Y | 5Y
0.0% | 0.1%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
CHF347.0m | CHF376.8m
EBITDA
CHF25.2m | CHF41.3m
EBIT
CHF-8.0m | CHF5.1m
Net Income
CHF-32.5m | CHF-13.7m
Free Cash Flow
CHF30.2m
Growth (TTM | estimate)
Revenue
13.2% | 18.8%
EBITDA
65.5% | 1,073.8%
EBIT
41.6% | 192.3%
Net Income
-21.6% | 25.1%
Free Cash Flow
6.8%
Margin (TTM | estimate)
Gross
11.6%
EBITDA
7.3% | 11.0%
EBIT
-2.3%
Net
-9.4% | -3.6%
Free Cash Flow
8.7%
Financial Health
Equity Ratio
47.2%
Return on Equity
-5.5%
ROCE
-1.5%
ROIC
-1.6%
Debt/Equity
0.3
More
EPS
CHF-1.0
FCF per Share
CHF0.9
Short interest
-
Employees
1k
Rev per Employee
CHF230.0k
Show more

Is PolyPeptide a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

PolyPeptide Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a PolyPeptide forecast:

8x Buy
73%
2x Hold
18%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a PolyPeptide forecast:

Buy
73%
Hold
18%
Sell
9%

Financial data from PolyPeptide

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
347 347
13% 13%
100%
- Direct Costs 307 307
10% 10%
88%
40 40
42% 42%
12%
- Selling and Administrative Expenses 47 47
16% 16%
14%
- Research and Development Expense 1.45 1.45
32% 32%
0%
25 25
66% 66%
7%
- Depreciation and Amortization 33 33
15% 15%
10%
EBIT (Operating Income) EBIT -7.98 -7.98
42% 42%
-2%
Net Profit -33 -33
22% 22%
-9%

In millions CHF.

Don't miss a Thing! We will send you all news about PolyPeptide directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.

Head office Switzerland
CEO Mr. Gonzalez
Employees 1,400
Founded 1996
Website www.polypeptide.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today